PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33592864-0 2021 Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer. Platinum 51-59 tumor protein p53 Homo sapiens 17-20 33744756-6 2021 Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells. Platinum 0-2 tumor protein p53 Homo sapiens 65-68 33375991-7 2021 Multivariate logistic regression was used to analyze the effects of TP53 mutation type on platinum resistance. Platinum 90-98 tumor protein p53 Homo sapiens 68-72 33375991-11 2021 TP53 mutations were associated with platinum sensitivity, even after adjusting for BRCA mutation status (OR 0.41, p = 0.048). Platinum 36-44 tumor protein p53 Homo sapiens 0-4 33375991-14 2021 After adjusting for BRCA mutations, TP53 mutations are associated with platinum sensitivity, and this effect is not dependent on TP53 mutation type. Platinum 71-79 tumor protein p53 Homo sapiens 36-40 33827148-7 2021 DNA damage response and apoptosis including the relationship between FOXOs and ATM-Chk2-p53 are essential for platinum resistance of ovarian cancer. Platinum 110-118 tumor protein p53 Homo sapiens 88-91 33592864-3 2021 METHODS: Pubmed, Web of Science, EMBASE, CNKI, China Wanfang databases were searched for studies on the relationship between the p53 expression and the chemosensitivity to platinum drugs in patients with NSCLC. Platinum 172-180 tumor protein p53 Homo sapiens 129-132 33592864-10 2021 CONCLUSION: Patients with p53 negative expression is more sensitive to platinum-based chemotherapy than those with p53 positive expression in NSCLC, especially in advanced NSCLC. Platinum 71-79 tumor protein p53 Homo sapiens 26-29 33592864-2 2021 This study aims to explore the correlation between p53 expression and sensitivity to platinum-based chemotherapy in patients with NSCLC. Platinum 85-93 tumor protein p53 Homo sapiens 51-54 33183422-0 2021 Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway. Platinum 15-23 tumor protein p53 Homo sapiens 95-98 32458023-3 2021 Following treatment with a platinum-based chemotherapeutic, there is a reduction in global levels of H2Bub1 accompanied by an increase in levels of the tumor suppressor p53. Platinum 27-35 tumor protein p53 Homo sapiens 169-172 32458023-6 2021 H2Bub1-enriched genes encompassed fifteen p53 target genes including PPM1D, BTG2, PLK2, MDM2, CDKN1A and BBC3, genes related to ERK/MAPK signalling, those participating in nucleotide excision repair including XPC, and genes involved in the immune response and platinum drug resistance including POLH. Platinum 260-268 tumor protein p53 Homo sapiens 42-45 32749686-17 2020 The results of the current study have highlighted the clinical value of EGFR and TP53 as predictive biomarkers of platinum-resistant recurrent and/or metastatic ESCC for afatinib sensitivity. Platinum 114-122 tumor protein p53 Homo sapiens 81-85 32611648-0 2020 A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Platinum 120-128 tumor protein p53 Homo sapiens 139-143 32382008-10 2020 Overall, our studies suggest that USP10 could be a potential biomarker for predicting patient response to platinum, and that targeting USP10 could sensitize lung cancer patients lacking wild-type p53 to platinum-based therapy. Platinum 203-211 tumor protein p53 Homo sapiens 196-199 32384200-1 2020 BACKGROUND: Testicular Germ Cell Tumors (TGCTs) are highly sensitive to platinum-based chemotherapy, and wild-type p53 seems to play a pivotal role in this susceptibility. Platinum 72-80 tumor protein p53 Homo sapiens 115-118 32910383-0 2020 Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy. Platinum 142-150 tumor protein p53 Homo sapiens 44-48 32477008-10 2020 KEGG analysis showed that the 28 differently expressed autophagy-related genes were related to platinum drug resistance, apoptosis and p53 signaling pathway. Platinum 95-103 tumor protein p53 Homo sapiens 135-138 32753889-6 2020 Nonsynonymous variants in EGFR, TTN, TP53 and KRAS, and copy number variations (SCNVs) in chromosome 8q24.3 and 22q11.21 were identified to be associated with platinum response. Platinum 159-167 tumor protein p53 Homo sapiens 37-41 32504383-1 2020 The effect of inhibition of the tumor suppressor p53 on the antioxidant system genes expression under the influence of cytotoxic compounds of the platinum group was studied. Platinum 146-154 tumor protein p53 Homo sapiens 49-52 32504383-2 2020 It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein. Platinum 32-40 tumor protein p53 Homo sapiens 96-99 32504383-2 2020 It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein. Platinum 32-40 tumor protein p53 Homo sapiens 225-228 32504383-2 2020 It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein. Platinum 49-57 tumor protein p53 Homo sapiens 96-99 32504383-2 2020 It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein. Platinum 49-57 tumor protein p53 Homo sapiens 225-228 32504383-4 2020 Suppression of p53 protein functions with specific inhibitor alpha-piphitrin under the action of platinum complexes reduced the expression of catalase and superoxide dismutase 2 genes and the target gene P21, which attested to the p53-dependent regulation of these genes. Platinum 97-105 tumor protein p53 Homo sapiens 15-18 32504383-4 2020 Suppression of p53 protein functions with specific inhibitor alpha-piphitrin under the action of platinum complexes reduced the expression of catalase and superoxide dismutase 2 genes and the target gene P21, which attested to the p53-dependent regulation of these genes. Platinum 97-105 tumor protein p53 Homo sapiens 231-234 32344513-7 2020 Second, we show that our siRNA-carrying nanoparticles enhanced platinum sensitivity in a p53 wildtype model of non-small cell lung cancer in vitro. Platinum 63-71 tumor protein p53 Homo sapiens 89-92 31798724-5 2019 CisPt decreased p53 protein phosphorylation in FaDu cells, but increased it in PE/CA-PJ49 cells. Platinum 0-5 tumor protein p53 Homo sapiens 16-19 31877751-0 2019 Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells. Platinum 45-53 tumor protein p53 Homo sapiens 62-66 31877751-7 2019 Interestingly, we found that PT-resistant MDAH cells acquired in the TP53 gene a novel secondary mutation (i.e., S185G) that accompanied the R273H typical of MDAH cells. Platinum 29-31 tumor protein p53 Homo sapiens 69-73 31877751-8 2019 The double p53S185G/R273H mutant increases the resistance to PT in a TP53 null EOC cellular model. Platinum 61-63 tumor protein p53 Homo sapiens 11-14 31877751-8 2019 The double p53S185G/R273H mutant increases the resistance to PT in a TP53 null EOC cellular model. Platinum 61-63 tumor protein p53 Homo sapiens 69-73 31877751-9 2019 Overall, we show how the selective pressure of PT is able to induce additional mutation in an already mutant TP53 gene in EOC and how this event could contribute to the acquisition of novel cellular phenotypes. Platinum 47-49 tumor protein p53 Homo sapiens 109-113 33166854-14 2020 CONCLUSION: Our study has identified that TP53 confers worse survival and response to platinum chemotherapy compared to BAP1. Platinum 86-94 tumor protein p53 Homo sapiens 42-46 31798724-9 2019 In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification. Platinum 19-24 tumor protein p53 Homo sapiens 50-53 31798724-9 2019 In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification. Platinum 19-24 tumor protein p53 Homo sapiens 115-118 31798724-9 2019 In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification. Platinum 19-24 tumor protein p53 Homo sapiens 115-118 31798724-10 2019 Moreover, in both tumor cell lines our results support the involvement of p53 phosphorylation-ERK1/2 activation-dependent in the apoptosis induced by combined treatments (CisPt and CRM). Platinum 171-176 tumor protein p53 Homo sapiens 74-77 31581548-7 2019 This study showed that (i) the splice mutation in TP53 was present as an early driver mutation at diagnosis; (ii) the mutational profile was shared in pre- and post-NACT tumor samples; (iii) the complete expansion of a single dominant mutant clone through loss of heterozygosity (LOH) had occurred, suggesting a possible mechanism of platinum-resistance in HGSOC under the pressure of NACT. Platinum 334-342 tumor protein p53 Homo sapiens 50-54 30896089-8 2019 Alterations within the TP53-MDM2 signal transduction pathway appear to be enriched among patients with platinum-resistant disease. Platinum 103-111 tumor protein p53 Homo sapiens 23-27 31295913-9 2019 Moreover, p53 and its family members (p63 and p73) might also be used as predictors of platinum response. Platinum 87-95 tumor protein p53 Homo sapiens 10-13 30339780-3 2019 This organometallic complex induced p53-independent cytotoxicity and reduced size and vascularization of patients-derived tumor explants that are resistant to platinum drugs. Platinum 159-167 tumor protein p53 Homo sapiens 36-39 30538112-6 2019 In addition, when p53 is disrupted by CRISPR-Cas9 (p53*) in ERCC1Delta/p53WT cells, there is reduced apoptosis and increased viability after platinum treatment. Platinum 141-149 tumor protein p53 Homo sapiens 18-21 30538112-6 2019 In addition, when p53 is disrupted by CRISPR-Cas9 (p53*) in ERCC1Delta/p53WT cells, there is reduced apoptosis and increased viability after platinum treatment. Platinum 141-149 tumor protein p53 Homo sapiens 51-54 30538112-10 2019 CONCLUSIONS: Our findings implicate p53 as a potential confounding variable in clinical assessments of ERCC1 as a platinum biomarker via promoting an environment in which error-prone mechanisms of ICL-R may be able to partially compensate for loss of ERCC1.See related commentary by Friboulet et al., p. 2369. Platinum 114-122 tumor protein p53 Homo sapiens 36-39 29307819-4 2018 In this study, the fluorescence lifetime of the metabolic coenzyme NADH reveals that the absence of REV3L can promote the p53-mediated upregulation of oxidative phosphorylation in cisplatin-treated H1299 lung carcinoma cells and increases cancer cell sensitivity to this platinum-based chemotherapy. Platinum 271-279 tumor protein p53 Homo sapiens 122-125 30205260-0 2018 Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway. Platinum 14-22 tumor protein p53 Homo sapiens 160-163 29690507-1 2018 The compound APR-246 (PRIMA-1MET) is a known reactivator of (mutant) p53 and inducer of oxidative stress which can sensitize cancer cells to platinum-based chemotherapeutics. Platinum 141-149 tumor protein p53 Homo sapiens 69-72 30301863-7 2019 Corroborating the basis of sensitivity, transcriptional profiling of platinum-resistant ARID1A-mutated HT1197 cells treated with panobinostat reveals negative enrichment for both cyto-proliferative (MYC and E2F targets) and DNA repair gene sets, and positive enrichment for TP53 and inflammatory gene sets. Platinum 69-77 tumor protein p53 Homo sapiens 274-278 30375398-9 2018 In addition, in platinum-treated patients with relapsed ovarian cancer, resistant period was positively correlated with the expression of PANDAR and SFRS2, and inversely associated with expression of p53-Ser15 and PUMA in these clinical tissues. Platinum 16-24 tumor protein p53 Homo sapiens 200-203 30106452-7 2018 Platinum increased p53 and p-p53 (ser15) in a time-dependent manner in 3D cultures. Platinum 0-8 tumor protein p53 Homo sapiens 19-22 30106452-7 2018 Platinum increased p53 and p-p53 (ser15) in a time-dependent manner in 3D cultures. Platinum 0-8 tumor protein p53 Homo sapiens 29-32 30106452-9 2018 Under 3D culture condition, knockdown of integrin beta4 did not detectably change the basal p53 protein level but increased p53 and p-p53 (ser15) protein accumulation induced by platinum. Platinum 178-186 tumor protein p53 Homo sapiens 124-127 30106452-9 2018 Under 3D culture condition, knockdown of integrin beta4 did not detectably change the basal p53 protein level but increased p53 and p-p53 (ser15) protein accumulation induced by platinum. Platinum 178-186 tumor protein p53 Homo sapiens 124-127 30106452-11 2018 Knockdown of wild-type p53 decreased sensitivity to platinum in 3D cultures. Platinum 52-60 tumor protein p53 Homo sapiens 23-26 30106452-12 2018 Since it has been proven that platinum damages DNA to kill cells and p53 plays a key role in the DNA damage response, our results indicated that integrin beta4 reduced DNA damage-induced p53 activation to decrease chemosensitivity in CRC. Platinum 30-38 tumor protein p53 Homo sapiens 187-190 29783665-3 2018 Here, a commercial NGS cancer panel comprising 26 genes, including TP53, was used to identify new genetic markers of platinum resistance and patient prognosis in a retrospective set of patients diagnosed with epithelial ovarian cancer. Platinum 117-125 tumor protein p53 Homo sapiens 67-71 29301826-0 2018 p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Platinum 75-83 tumor protein p53 Homo sapiens 0-3 29301826-0 2018 p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Platinum 75-83 tumor protein p53 Homo sapiens 143-146 26086967-1 2015 Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular glutathione concentration. Platinum 19-27 tumor protein p53 Homo sapiens 81-85 28494179-10 2017 p53 family members and molecular subtypes of TNBC are also important alternative considerations for predicting platinum response based on the preclinical trials. Platinum 111-119 tumor protein p53 Homo sapiens 0-3 28730758-6 2017 This paper summarizes data about platinum derivatives through a multidisciplinary approach, starting from a chemical point of view and on to their mechanism of action, mechanism of cellular resistance, predictive factors for the outcome of chemotherapy such as micro RNAs (miRNAs), tumor suppressor protein p53, and the excision repair cross-complementing 1 protein (ERCC1). Platinum 33-41 tumor protein p53 Homo sapiens 307-310 28031409-0 2017 Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Platinum 39-47 tumor protein p53 Homo sapiens 32-35 28031409-3 2017 The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2. Platinum 55-63 tumor protein p53 Homo sapiens 159-162 28031409-3 2017 The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2. Platinum 55-63 tumor protein p53 Homo sapiens 214-217 27313779-5 2016 Platinum increased p53 in a dose-dependent and time-dependent manner. Platinum 0-8 tumor protein p53 Homo sapiens 19-22 27313779-8 2016 Knockdown of p53 significantly decreased sensitivity to platinum in 3D cultures. Platinum 56-64 tumor protein p53 Homo sapiens 13-16 27313779-13 2016 Taken together, our results suggest that p53 is involved in a 3D architecture-mediated decrease in chemosensitivity to platinum in colon cancer. Platinum 119-127 tumor protein p53 Homo sapiens 41-44 26334096-0 2015 A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Platinum 88-96 tumor protein p53 Homo sapiens 55-58 26269716-6 2015 We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy. Platinum 107-115 tumor protein p53 Homo sapiens 139-143 26269716-6 2015 We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy. Platinum 194-202 tumor protein p53 Homo sapiens 139-143 27998224-3 2016 We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)-mutated ovarian cancer refractory or resistant (< 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies. Platinum 177-185 tumor protein p53 Homo sapiens 66-69 27998224-3 2016 We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)-mutated ovarian cancer refractory or resistant (< 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies. Platinum 177-185 tumor protein p53 Homo sapiens 94-98 27614750-0 2016 Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy. Platinum 104-112 tumor protein p53 Homo sapiens 15-18 27191893-6 2016 However, when stratified by chemotherapy regimen, patients whose tumors had TP53 and HR mutations demonstrated a marked survival advantage when treated with platinum and paclitaxel vs. platinum +/- cyclophosphamide (median OS of 90 months (95% CI 50-NA) vs. 29.5 months (95% CI 17.7-50.5), p = 0.0005). Platinum 157-165 tumor protein p53 Homo sapiens 76-80 27191893-6 2016 However, when stratified by chemotherapy regimen, patients whose tumors had TP53 and HR mutations demonstrated a marked survival advantage when treated with platinum and paclitaxel vs. platinum +/- cyclophosphamide (median OS of 90 months (95% CI 50-NA) vs. 29.5 months (95% CI 17.7-50.5), p = 0.0005). Platinum 185-193 tumor protein p53 Homo sapiens 76-80 25263447-0 2015 p53 protein aggregation promotes platinum resistance in ovarian cancer. Platinum 33-41 tumor protein p53 Homo sapiens 0-3 26086967-7 2015 We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutathione has a key role in the resensitization as well as in the outstanding synergistic effects observed with APR-246 in combination with platinum compounds in ovarian cancer cell lines and primary cancer cells. Platinum 236-244 tumor protein p53 Homo sapiens 86-89 26086967-10 2015 Our results provide a strong rationale for the ongoing clinical study with APR-246 in combination with platinum-based therapy in patients with p53-mutant recurrent high-grade serous (HGS) ovarian cancer. Platinum 103-111 tumor protein p53 Homo sapiens 143-146 26086967-12 2015 Combined treatment with APR-246 and platinum or other DNA-damaging drugs could allow dramatically improved therapy of a wide range of therapy refractory p53 mutant tumors. Platinum 36-44 tumor protein p53 Homo sapiens 153-156 25385265-0 2015 TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Platinum 49-57 tumor protein p53 Homo sapiens 0-4 25691460-0 2015 Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Platinum 67-75 tumor protein p53 Homo sapiens 29-33 25385265-9 2015 Patients with oncomorphic TP53 mutations demonstrated significantly worse PFS, a 60% higher risk of recurrence (HR=1.60, 95% confidence intervals 1.09, 2.33, p=0.015), and higher rates of platinum resistance (chi(2) test p=0.0024) when compared with single nucleotide mutations not categorized as oncomorphic. Platinum 188-196 tumor protein p53 Homo sapiens 26-30 25407898-0 2015 Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction. Platinum 23-31 tumor protein p53 Homo sapiens 33-36 25142144-6 2014 Genotype data for the TP53-Arg72Pro polymorphism, which is associated with responses to platinum-based doublet chemotherapy, were subsequently incorporated into the prediction analysis. Platinum 88-96 tumor protein p53 Homo sapiens 22-26 24463159-0 2014 TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Platinum 31-39 tumor protein p53 Homo sapiens 0-4 24463159-10 2014 CONCLUSIONS: TP53 K351N mutation may be associated with induction of platinum resistance after NACT in advanced EOC. Platinum 69-77 tumor protein p53 Homo sapiens 13-17 25250341-5 2014 RESULTS: ERCC1 118C and TP53 72Arg polymorphisms were associated with increased risks of platinum-induced nephrotoxicity. Platinum 89-97 tumor protein p53 Homo sapiens 24-28 22331493-11 2012 Hyperthermia +- sodium arsenite enhanced cellular and DNA accumulation of platinum in wild-type p53-expressing cells. Platinum 74-82 tumor protein p53 Homo sapiens 96-99 25482940-2 2014 In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy. Platinum 126-134 tumor protein p53 Homo sapiens 47-50 22331493-0 2012 Sodium arsenite +- hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Platinum 112-120 tumor protein p53 Homo sapiens 43-46 22331493-3 2012 P53 plays a critical role in cellular response to DNA damage and has been implicated in EOC response to platinum chemotherapy. Platinum 104-112 tumor protein p53 Homo sapiens 0-3 22331493-12 2012 Only hyperthermia enhanced platinum accumulation in p53-null cells. Platinum 27-35 tumor protein p53 Homo sapiens 52-55 22333583-0 2012 Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Platinum 72-80 tumor protein p53 Homo sapiens 45-48 20940192-6 2010 CONCLUSION: Polymorphisms in the TP53 and PARP1 genes are involved in inter-individual differences in the response to platinum-based doublet chemotherapy in patients with NSCLC. Platinum 118-126 tumor protein p53 Homo sapiens 33-37 23936624-1 2012 A texaphyrin-oxaliplatin conjugate, oxaliTEX, was designed to test the concept that a platinum analog can overcome defects in drug accumulation and p53-dependent DNA damage response in a tumor model expressing multifactorial mechanisms of cisplatin resistance. Platinum 86-94 tumor protein p53 Homo sapiens 148-151 22590594-2 2012 Deregulation of p53 and/or p73-associated apoptotic pathways contribute to the platinum-based resistance in ovarian cancer. Platinum 79-87 tumor protein p53 Homo sapiens 16-19 22331725-0 2011 TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas. Platinum 68-76 tumor protein p53 Homo sapiens 0-4 21863213-3 2011 The p53 mutation correlates significantly with resistance to platinum-based chemotherapy, early relapse and shortened overall survival in ovarian cancer patients. Platinum 61-69 tumor protein p53 Homo sapiens 4-7 23285001-6 2012 Furthermore, patients with high p53 expression in tumors acquired remarkable survival benefit from adjuvant first-line platinum-based-chemotherapy. Platinum 119-127 tumor protein p53 Homo sapiens 32-35 23285001-8 2012 Thus, p53 expression is a potent prognostic and predictive factor for resectable gastric cancer with adjuvant platinum-based chemotherapy. Platinum 110-118 tumor protein p53 Homo sapiens 6-9 22075440-8 2011 CONCLUSIONS: It appears that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients. Platinum 117-125 tumor protein p53 Homo sapiens 29-33 21927014-0 2011 Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells. Platinum 0-8 tumor protein p53 Homo sapiens 78-81 21792013-1 2011 BACKGROUND: In non-small cell lung cancer, expression of excision repair cross-complementation group 1 (ERCC1) and p53 correlates with platinum resistance and class III beta-tubulin with resistance to taxanes. Platinum 135-143 tumor protein p53 Homo sapiens 115-118 20047843-9 2010 While limited clinical data suggest that p53 mutations are associated with resistance to platinum-based therapies in NSCLC, data on p53 IHC positivity are equivocal. Platinum 89-97 tumor protein p53 Homo sapiens 41-44 20562210-10 2010 CONCLUSIONS: ALC was effective in enhancing the antitumor potential of platinum compounds in wild-type p53 tumors. Platinum 71-79 tumor protein p53 Homo sapiens 103-106 20025464-0 2010 DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles. Platinum 70-78 tumor protein p53 Homo sapiens 15-18 19499188-0 2010 The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Platinum 79-87 tumor protein p53 Homo sapiens 39-42 20101229-4 2010 p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032). Platinum 69-77 tumor protein p53 Homo sapiens 0-3 19854294-2 2010 Our explorative pathway analysis on seven published gene-sets associated with platinum resistance in ovarian cancer reveals TP53 and transforming growth factor beta as key genes. Platinum 78-86 tumor protein p53 Homo sapiens 124-128 19609560-2 2010 The objective of this study was to explore the value of the p53 mutational status, using four different techniques, in advanced OC patients as a predictive marker for responsiveness to platinum-based chemotherapy. Platinum 185-193 tumor protein p53 Homo sapiens 60-63 20719132-2 2009 It has been proven that ERCC1, RRM1, p53 expressions were related to resistance to platinum and prognosis of the patcents with lung cancer. Platinum 83-91 tumor protein p53 Homo sapiens 37-40 18507046-6 2008 Platinum sensitivity was associated with heterozygosity at the TP53 locus (p = 0.006). Platinum 0-8 tumor protein p53 Homo sapiens 63-67 18575867-4 2009 The H69 cells and resistant cell lines have a p53 mutation and consequently decrease expression of p21 in response to platinum drug treatment, promoting progression of the cell cycle instead of increasing p21 to maintain the arrest. Platinum 118-126 tumor protein p53 Homo sapiens 46-49 19150122-1 2009 OBJECTIVE: The aim of the study was to evaluate the prognostic significance of p53 and PTEN in patients with epithelial ovarian cancer who were treated with taxane and platinum-based chemotherapy. Platinum 168-176 tumor protein p53 Homo sapiens 79-82 18937971-6 2009 Platinum highly sensitive response showed a positive association with TP53 accumulation (p=0.045). Platinum 0-8 tumor protein p53 Homo sapiens 70-74 18193228-0 2008 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway. Platinum 47-50 tumor protein p53 Homo sapiens 179-182 18193228-13 2008 PT-262 elicited the cytotoxicity and accumulated the G2/M fractions in both the p53-wild type and p53-null lung cancer cells. Platinum 0-2 tumor protein p53 Homo sapiens 80-83 18193228-13 2008 PT-262 elicited the cytotoxicity and accumulated the G2/M fractions in both the p53-wild type and p53-null lung cancer cells. Platinum 0-2 tumor protein p53 Homo sapiens 98-101 18230133-6 2008 RESULTS: The advantage of taxane-platinum therapy over platinum-based therapy was seen in the TP53(+), and not in the TP53(-) group. Platinum 33-41 tumor protein p53 Homo sapiens 94-98 18281754-4 2008 Glutathione S-transferase-pi and metallo- thionein have been related to the metabolism of platinum drugs, excision repair cross-complementing 1/2 to DNA repair systems, and p53 to apoptosis. Platinum 90-98 tumor protein p53 Homo sapiens 173-176 18230133-6 2008 RESULTS: The advantage of taxane-platinum therapy over platinum-based therapy was seen in the TP53(+), and not in the TP53(-) group. Platinum 55-63 tumor protein p53 Homo sapiens 94-98 17686239-12 2007 CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer. Platinum 95-103 tumor protein p53 Homo sapiens 28-31 18230133-7 2008 In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008). Platinum 28-36 tumor protein p53 Homo sapiens 7-11 18230133-7 2008 In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008). Platinum 104-112 tumor protein p53 Homo sapiens 7-11 18230133-7 2008 In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008). Platinum 104-112 tumor protein p53 Homo sapiens 7-11 18230133-8 2008 Poor tumor differentiation diminished the advantage from taxane-platinum therapy in the TP53(+) group. Platinum 64-72 tumor protein p53 Homo sapiens 88-92 18230133-9 2008 In the TP53(-) group PC/PAC was at least equally efficient as taxane-platinum therapy and it enhanced the chance of platinum highly sensitive response (p = .010). Platinum 116-124 tumor protein p53 Homo sapiens 7-11 18230133-10 2008 However, in the TP53(-) group taxane-platinum therapy possibly diminished the risk of death in patients over 53 yrs (p = .077). Platinum 37-45 tumor protein p53 Homo sapiens 16-20 18230133-12 2008 CONCLUSION: Our results suggest that taxane-platinum therapy is particularly justified in patients with TP53(+) tumors or older than 53 years. Platinum 44-52 tumor protein p53 Homo sapiens 104-108 18230133-13 2008 In the group of patients < or =53 yrs and with TP53(-) tumors platinum-based therapy is possibly equally efficient. Platinum 65-73 tumor protein p53 Homo sapiens 50-54 17640298-1 2007 Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs. Platinum 143-151 tumor protein p53 Homo sapiens 69-72 18172257-10 2008 CONCLUSION: Our study provides evidence that both germ line and somatic alterations of the p53 pathway influence the incidence and survival of ovarian carcinoma, and it underscores the importance of assessing the functionality of p53 in order to predict the sensitivity of platinum-based chemotherapies and patient outcome. Platinum 273-281 tumor protein p53 Homo sapiens 91-94 15486204-0 2004 Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Platinum 111-119 tumor protein p53 Homo sapiens 57-60 16739339-0 2006 P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Platinum 119-127 tumor protein p53 Homo sapiens 0-3 16750013-0 2006 [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]. Platinum 77-85 tumor protein p53 Homo sapiens 110-113 16750013-2 2006 This study examined the relationship between p53 and p73 genetic polymorphisms and the response to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Platinum 99-107 tumor protein p53 Homo sapiens 45-48 16750013-10 2006 CONCLUSION: Those results suggest that p53 and p73 polymorphisms may be associated with clinical responsiveness to platinum-based chemotherapy in advanced NSCLC. Platinum 115-123 tumor protein p53 Homo sapiens 39-42 16322298-1 2005 PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72. Platinum 112-120 tumor protein p53 Homo sapiens 56-59 16322298-1 2005 PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72. Platinum 112-120 tumor protein p53 Homo sapiens 75-78 16322298-1 2005 PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72. Platinum 112-120 tumor protein p53 Homo sapiens 75-78 16322298-10 2005 p53 mutational status was an important determinant of responsiveness to platinum-based chemotherapy in all patients with a residual tumor of <2 cm in diameter after initial surgery (wild-type versus mutant, P = 0.029). Platinum 72-80 tumor protein p53 Homo sapiens 0-3 16127286-7 2005 This outcome is consistent with the clinical observation that the efficacy of topotecan in the treatment of relapsed ovarian carcinoma patients is dependent on platinum sensitivity, because platinum-sensitive tumors are expected to carry wild-type p53. Platinum 160-168 tumor protein p53 Homo sapiens 248-251 16127286-7 2005 This outcome is consistent with the clinical observation that the efficacy of topotecan in the treatment of relapsed ovarian carcinoma patients is dependent on platinum sensitivity, because platinum-sensitive tumors are expected to carry wild-type p53. Platinum 190-198 tumor protein p53 Homo sapiens 248-251 15486204-5 2004 DNA is a major pharmacological target of platinum compounds and DNA binding activity of the p53 protein is crucial for its tumor suppressor function. Platinum 41-49 tumor protein p53 Homo sapiens 92-95 14729645-6 2004 For example, the functionality of the p53-activated pathway appeared positively correlated with the cytotoxicity of all platinum compounds. Platinum 120-128 tumor protein p53 Homo sapiens 38-41 14513366-0 2003 Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Platinum 101-109 tumor protein p53 Homo sapiens 10-13 14513366-1 2003 PURPOSE: Resistance to chemotherapeutic drugs is a hallmark of many human cancers, which can occur independent of p53 gene status; however, the presence of wild-type p53 in chemorefractory tumors confers greater resistance to cisplatin, but such tumors do not display complete cross-resistance to the platinum analog (1R,2R-diaminocyclohexane)(trans-diacetato)(dichloro)platinumIV (DACH-Ac-Pt). Platinum 301-309 tumor protein p53 Homo sapiens 166-169 12570658-0 2003 Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Platinum 38-46 tumor protein p53 Homo sapiens 66-69 12684687-4 2003 We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel. Platinum 232-240 tumor protein p53 Homo sapiens 35-38 12570658-9 2003 Thus, platinum compounds are endowed with differential capability to activate pathways of p53-dependent or independent apoptosis, and differential recognition by specific cellular systems is likely to be the critical determinant of the cell fate (death/survival) after drug exposure. Platinum 6-14 tumor protein p53 Homo sapiens 90-93 12499281-0 2002 Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Platinum 150-158 tumor protein p53 Homo sapiens 79-82 12499281-11 2002 Taken together, p53 has a significant role in the cellular response to chemoradiation treatment in cervical cancer cell lines, but p53 activity may have a dramatically different effect on cell survival depending on the platinum carrier ligand. Platinum 219-227 tumor protein p53 Homo sapiens 131-134 12468337-1 2002 OBJECTIVE: The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Platinum 163-171 tumor protein p53 Homo sapiens 77-80 12478472-0 2002 Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Platinum 39-47 tumor protein p53 Homo sapiens 143-146 12478472-1 2002 Mononuclear and multinuclear platinum complexes are known to induce distinct types of DNA lesions and exhibit different profiles of antitumor activity, in relation to p53 mutational status. Platinum 29-37 tumor protein p53 Homo sapiens 167-170 12478472-8 2002 Multinuclear platinum complexes could be regarded as useful tools for investigating the p53-mediated process of cell cycle arrest in response to DNA damage. Platinum 13-21 tumor protein p53 Homo sapiens 88-91 12440809-5 2002 In ovarian cancer p53 status is a strong predictor of response to platinum-based chemotherapy. Platinum 66-74 tumor protein p53 Homo sapiens 18-21 12006509-2 2002 The purpose of this study was to examine p53 mutations in leukemias after ovarian cancer, for which treatment with platinum analogues was widely used. Platinum 115-123 tumor protein p53 Homo sapiens 41-44 12093475-1 2002 The aim of this study is to establish anti-tumour potency of the new oral platinum drug JM216 and its metabolite JM118 in relation to the platinum (Pt)-DNA adduct formation, glutathione (GSH)-levels, and p53 status in human cancer cell lines with different sensitivities to cisplatin (CDDP). Platinum 74-82 tumor protein p53 Homo sapiens 204-207 12440809-6 2002 Patients whose tumors have p53 mutations experience a lower chance of achieving a complete response following platinum-based regimens when compared to patients without p53 mutations. Platinum 110-118 tumor protein p53 Homo sapiens 27-30 12440809-8 2002 Whereas patients with wild-type p53 tumors have a good chance to respond to platinum, patients with mutant p53 tumors may have a clinical benefit from the addition of paclitaxel to platinum-based chemotherapy. Platinum 76-84 tumor protein p53 Homo sapiens 32-35 12440809-8 2002 Whereas patients with wild-type p53 tumors have a good chance to respond to platinum, patients with mutant p53 tumors may have a clinical benefit from the addition of paclitaxel to platinum-based chemotherapy. Platinum 181-189 tumor protein p53 Homo sapiens 107-110 11279186-1 2001 The p53 gene encodes a nuclear phosphoprotein that is biologically activated in response to genotoxic stresses including treatment with anticancer platinum drugs. Platinum 147-155 tumor protein p53 Homo sapiens 4-7 11720475-4 2001 Using molecular and immunohistochemical analyses we examined TP53 and its downstream genes p21, BAX and BCL-2 in ovarian tumour tissues and have evaluated the results in relation to clinico-pathological parameters, clinical outcome and response to platinum-based chemotherapy. Platinum 248-256 tumor protein p53 Homo sapiens 61-65 11595686-0 2001 Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Platinum 48-56 tumor protein p53 Homo sapiens 15-18 11595686-9 2001 CONCLUSIONS: p53 alterations correlate significantly with resistance to platinum-based chemotherapy, early relapse, and shortened overall survival in ovarian cancer patients in univariate analysis. Platinum 72-80 tumor protein p53 Homo sapiens 13-16 10955812-0 2000 Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Platinum 180-188 tumor protein p53 Homo sapiens 44-47 11099323-1 2000 PURPOSE: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Platinum 122-130 tumor protein p53 Homo sapiens 13-16 11099323-2 2000 Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy. Platinum 168-176 tumor protein p53 Homo sapiens 85-88 9891541-0 1998 p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Platinum 89-97 tumor protein p53 Homo sapiens 0-3 10692490-0 2000 Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Platinum 39-47 tumor protein p53 Homo sapiens 10-13 10692490-10 2000 Our results suggest that the loss of functional p53 can increase cisplatin cytotoxicity in A2780, with loss of G(1)/S checkpoint control and decreased cisplatin-DNA adduct repair, but these effects can be circumvented by the use of JM335, which forms different DNA-platinum adducts. Platinum 265-273 tumor protein p53 Homo sapiens 48-51 10637254-1 2000 PURPOSE: To determine whether p53 gene status predicts tumor responses to platinum- and fluorouracil-based induction chemotherapy in locoregionally advanced squamous cell carcinomas of the head and neck. Platinum 74-82 tumor protein p53 Homo sapiens 30-33 10100719-0 1999 Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Platinum 94-102 tumor protein p53 Homo sapiens 14-17 10100719-6 1999 Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M. Platinum 28-36 tumor protein p53 Homo sapiens 130-133 10100719-6 1999 Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M. Platinum 28-36 tumor protein p53 Homo sapiens 192-195 10100719-6 1999 Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M. Platinum 28-36 tumor protein p53 Homo sapiens 192-195 10471039-0 1999 A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Platinum 27-35 tumor protein p53 Homo sapiens 111-114 10471039-8 1999 The results showed that the transfer of functional p53 resulted in a marked (tenfold) reduction of cellular chemosensitivity to the multinuclear platinum complex but in a moderate sensitization to cisplatin. Platinum 145-153 tumor protein p53 Homo sapiens 51-54 9797696-10 1998 There was a statistically significant dose-response effect of platinum-based chemotherapy in patients with p53 negative tumours, which could not be seen in patients with p53 positive tumours (P = 0.01 versus P = 0.553). Platinum 62-70 tumor protein p53 Homo sapiens 107-110 9714063-11 1998 Our results suggest an overall association between wild type P53 and radiation and platinum drug sensitivity in these ovarian cancer cell lines. Platinum 83-91 tumor protein p53 Homo sapiens 61-64 21544361-0 1996 Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Platinum 0-8 tumor protein p53 Homo sapiens 126-129 9464331-10 1998 Accordingly, consolidation chemotherapy is necessary for patients with stage I a who are positive p53 and highly PA. Platinum-based chemotherapy for patients who had minimal residual tumor was effective, but 5 patients who had > or = 2 cm tumor burden were not effective at all. Platinum 117-125 tumor protein p53 Homo sapiens 98-101 9464331-11 1998 The response rate for platinum-based chemotherapy was 20% (1/5) among p53 positive, in contrast to 66.7% (4/6) among p53 negative patients. Platinum 22-30 tumor protein p53 Homo sapiens 70-73 9042215-4 1996 Among the 21 patients with stage III-IV disease, a complete clinical response to front-line platinum-based chemotherapy was obtained by 46.2% of the 13 patients without anti-p53 antibodies and 25.0% of the 8 patients with anti-p53 antibodies. Platinum 92-100 tumor protein p53 Homo sapiens 174-177 9042215-4 1996 Among the 21 patients with stage III-IV disease, a complete clinical response to front-line platinum-based chemotherapy was obtained by 46.2% of the 13 patients without anti-p53 antibodies and 25.0% of the 8 patients with anti-p53 antibodies. Platinum 92-100 tumor protein p53 Homo sapiens 227-230 21544361-2 1996 We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors. Platinum 97-105 tumor protein p53 Homo sapiens 210-213 21544361-0 1996 Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Platinum 23-31 tumor protein p53 Homo sapiens 126-129 21544361-2 1996 We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors. Platinum 17-25 tumor protein p53 Homo sapiens 72-75 21544361-2 1996 We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors. Platinum 17-25 tumor protein p53 Homo sapiens 210-213 21544361-2 1996 We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors. Platinum 97-105 tumor protein p53 Homo sapiens 210-213 21544361-2 1996 We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors. Platinum 97-105 tumor protein p53 Homo sapiens 210-213 34647981-13 2021 TP53 CHIP was associated with longer prior exposure to platinum (mean 14.0 months of 15 TP53 CHIP cases vs 11.1 months of 49 non-TP53 CHIP cases; P = .02). Platinum 55-63 tumor protein p53 Homo sapiens 0-4 32796711-0 2020 Cellular Responses to Platinum-Based Anticancer Drugs and UVC: Role of p53 and Implications for Cancer Therapy. Platinum 22-30 tumor protein p53 Homo sapiens 71-74 34963005-10 2022 This observation was due to a statistically significantly increased number of platinum-based chemotherapy lines in gBRCA1/2 mutation carriers vs noncarriers (PPM1D: mean (SD) = 2.04 (1.27) vs 1.04 (0.99), P < .001; TP53: mean (SD) =2.83 (1.33) vs 1.07 (1.01), P < .001). Platinum 78-86 tumor protein p53 Homo sapiens 215-219 34967559-0 2021 Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients. Platinum 57-65 tumor protein p53 Homo sapiens 18-22 34967559-4 2021 Therefore, this study aimed to investigate XPD Lys751Gln and TP53 Arg72Pro polymorphisms on the risk of platinum-based chemotherapy-induced toxicity in lung cancer patients in the Bangladeshi population. Platinum 104-112 tumor protein p53 Homo sapiens 61-65 34794242-0 2021 The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways. Platinum 25-27 tumor protein p53 Homo sapiens 110-113 34647981-13 2021 TP53 CHIP was associated with longer prior exposure to platinum (mean 14.0 months of 15 TP53 CHIP cases vs 11.1 months of 49 non-TP53 CHIP cases; P = .02). Platinum 55-63 tumor protein p53 Homo sapiens 88-92 34298618-9 2021 Collectively, our findings implicate nuclear HKII-P-p53(Ser15) interaction in chemosensitivity and could provide an effective clinical strategy as a promising biomarker during platinum-based therapy. Platinum 176-184 tumor protein p53 Homo sapiens 52-55 35598358-7 2022 TP53 mutations and brain metastases were associated with shorter PFS under platinum doublets and EGFR inhibitors (HR 3.3-6.1, p < 0.01), and shorter OS for patients receiving both treatments (p < 0.05). Platinum 75-83 tumor protein p53 Homo sapiens 0-4 34141624-9 2021 Variant clonality and co-occuring TP53 variants affect the predictive value of HRR pathogenic variants for platinum agents in patients with EOC. Platinum 107-115 tumor protein p53 Homo sapiens 34-38